Molecular Targeting Technologies (MTTI) is a leading biotechnology company specializing in the development of innovative diagnostic and therapeutic molecules. With a strong focus on cancer and cardiovascular diseases, MTTI aims to address pressing medical needs. The company's flagship products, PSVue and Tc-99m Duramycin, have emerged as promising lead candidates in the field.

These cutting-edge solutions offer new possibilities for accurate diagnosis and effective treatment. In addition, MTTI has established itself as a trusted provider of research reagents. They offer a diverse range of products, primarily based on fluorescence, to cater to the evolving needs of academic researchers.

Committed to scientific advancement, MTTI also offers custom chemistry services to support researchers in their pursuit of breakthroughs. With a dedication to excellence and a passion for innovation, Molecular Targeting Technologies continues to redefine the boundaries of medical science. Visit the MTTI website to learn more about their transformative solutions and ongoing research efforts